SIRPα blockade therapy potentiates immunotherapy by inhibiting PD-L1⁺ myeloid cells in hepatocellular carcinoma.

ABSTRACT: Tumor-infiltrating myeloid cells (TIMs) are pivotal cell populations involved in the immunosuppressive tumor immune microenvironment (TIME). However, there has been little success in large-scale clinical trials of myeloid cell modulators. We aim to investigate potential molecular targets for TIMs and disclose the underlying mechanism. Using mass cytometry by time of flight (CyTOF), we analyzed 24 spontaneous HCC tissues from mouse. Orthotopic and subcutaneous tumor models were established with or without anti-SIRPα antibody treatment. Patient-derived tumor xenografts model (PDX) was used to identify the CD47-SIRPα axis blocked therapy. In 24 murine spontaneous HCC tissues, we observed that the proportion of myeloid-derived suppressor cells (MDSCs) plus macrophages accounts for 40-90% of TI

SUBMITTER: Huang D 

PROVIDER: S-EPMC12170831 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature